Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation
Phase 2 Completed
40 enrolled 17 charts
Epigenetic Reprogramming in Relapse/Refractory AML
Phase 1 Completed
37 enrolled 11 charts
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Phase 1/2 Completed
34 enrolled 18 charts
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Phase 2 Completed
15 enrolled 15 charts
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
Phase 2 Completed
11 enrolled 12 charts
Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor(CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL
Phase 1 Completed
19 enrolled
Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
Phase 1/2 Completed
18 enrolled 30 charts
Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma
Phase 1 Completed
8 enrolled
CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome
Phase 1 Completed
14 enrolled
BMT CTN 0903
Phase 2 Completed
20 enrolled 25 charts
Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
Phase 2 Completed
82 enrolled 18 charts
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
Phase 2 Completed
422 enrolled 19 charts
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia
Phase 3 Completed
6,136 enrolled
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
Phase 1/2 Completed
43 enrolled 19 charts
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase 3 Completed
256 enrolled 13 charts
Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)
Phase 2 Completed
289 enrolled 8 charts
Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants
Phase 2 Completed
116 enrolled 14 charts
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
Phase 1 Completed
7 enrolled
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
Phase 2 Completed
24 enrolled 8 charts
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention
Phase 1 Completed
5 enrolled
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
Phase 2 Completed
295 enrolled 27 charts
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
Phase 1/2 Completed
47 enrolled 8 charts
NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents
Phase 2 Completed
7 enrolled
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
Phase 2 Completed
22 enrolled 5 charts
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
Phase 2 Completed
20 enrolled 9 charts
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
Phase 2 Completed
73 enrolled 16 charts
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
Phase 2 Completed
176 enrolled 18 charts
Cord Blood Expansion on Mesenchymal Stem Cells
Phase 1 Completed
98 enrolled
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
Phase 1/2 Completed
282 enrolled 13 charts
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
Phase 1/2 Completed
40 enrolled
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Phase 1 Completed
28 enrolled
Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)
Phase 1/2 Completed
177 enrolled
Reduced Intensity Double Umbilical Cord Blood Transplantation
Phase 2 Completed
33 enrolled 19 charts
Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)
Phase 2 Completed
22 enrolled 6 charts
Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide
Phase 1 Completed
127 enrolled
Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine
Phase 2 Completed
45 enrolled 12 charts
Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline
Phase 2 Completed
66 enrolled 7 charts
CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)
Phase 1 Completed
30 enrolled
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Phase 1 Completed
46 enrolled 11 charts
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
Phase 1 Completed
33 enrolled
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
Phase 2 Completed
56 enrolled 10 charts
Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Phase 2 Completed
151 enrolled 3 charts
Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant
Phase 2 Completed
12 enrolled 6 charts
Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
Phase 2 Completed
65 enrolled 8 charts
Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG
Phase 2 Completed
6 enrolled 3 charts
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor
Phase 2 Completed
96 enrolled 5 charts
Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia
Phase NA Completed
2 enrolled 4 charts
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase 1 Completed
15 enrolled
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Phase 1/2 Completed
92 enrolled 5 charts
Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia
Phase 2 Completed
25 enrolled 7 charts